Display options
Cite
Garcia N, Sanyal AJ. Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia. Curr Treat Options Gastroenterol. 2001;4(2):163-171doi: 10.1007/s11938-001-0028-0.
Garcia, N., & Sanyal, A. J. (2001). Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia. Current treatment options in gastroenterology, 4(2), 163-171. https://doi.org/10.1007/s11938-001-0028-0
Garcia, Nelson, and Sanyal, Arun J.. "Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia." Current treatment options in gastroenterology vol. 4,2 (2001): 163-171. doi: https://doi.org/10.1007/s11938-001-0028-0
Garcia N, Sanyal AJ. Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia. Curr Treat Options Gastroenterol. 2001 Apr;4(2):163-171. doi: 10.1007/s11938-001-0028-0. PMID: 11469974.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Gastroenterol. 2001 Apr;4(2):163-171. doi: 10.1007/s11938-001-0028-0.

Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia.

Current treatment options in gastroenterology

Nelson Garcia, Arun J. Sanyal

Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Virginia-Virginia Commonwealth University, PO Box 980711, Richmond, VA 23298-0711, USA. [email protected]

PMID: 11469974 DOI: 10.1007/s11938-001-0028-0

Abstract

Portal hypertensive gastropathy (PHG) causes both acute and chronic blood loss from the gastrointestinal tract in patients with portal hypertension. Gastric antral vascular ectasia (GAVE) is a distinct condition also associated with portal hypertension that can cause acute and chronic upper gastrointestinal blood loss. These conditions frequently, but not invariably, are diagnosed by upper endoscopy. Although they are fairly prevalent, only 15% to 20% of subjects experience symptomatic gastrointestinal blood loss. Acute gastrointestinal bleeding from PHG should first be treated with octreotide (100 mg bolus intravenously, followed by a 50 mg/h continuous intravenous infusion). If the bleeding does not stop or slow down appreciably within 24 to 48 hours, propranolol may be administered orally to those patients who are hemodynamically stable. Propranolol should be started at 40 mg/d orally in two divided doses. If the patient can tolerate the propranolol and is still bleeding, the dosage may be titrated up to the maximum tolerated amount. For those subjects who are unable to tolerate beta-blockers or continue to bleed despite beta-blocker therapy, transjugular intrahepatic portosystemic shunt (TIPS) is the next line of treatment. Portal decompressive surgery is reserved for those who are not candidates for TIPS and where the appropriate expertise is available. Prevention of chronic gastrointestinal blood loss from PHG should be attempted with beta-blockers, with the dosage titrated up to achieve a resting heart rate of approximately 60 beats per minute. In patients who do not respond to beta-blockers, a TIPS should be placed. The role of long-acting release octreotide in this setting is experimental. The primary treatment of actively bleeding GAVE as well as recurrent bleeding from GAVE is endoscopic ablation of the lesion using either argon plasma coagulation, neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, or heater probe. TIPS and beta-blockers are ineffective for the long-term prevention of recurrent bleeding from GAVE. For selected patients with severe recurrent bleeding or uncontrollable acute bleeding from GAVE, an antrectomy with Billroth I anastomosis may be considered.

References

  1. Metabolism. 1992 Sep;41(9 Suppl 2):22-33 - PubMed
  2. Gastroenterology. 2000 May;118(5):905-11 - PubMed
  3. Gastroenterology. 1992 Mar;102(3):994-9 - PubMed
  4. J Gastroenterol Hepatol. 1996 Sep;11(9):832-4 - PubMed
  5. Am J Gastroenterol. 1999 Oct;94(10):2909-11 - PubMed
  6. Gastroenterology. 1995 Jan;108(1):138-44 - PubMed
  7. Hepatology. 1993 Jul;18(1):36-40 - PubMed
  8. Hepatology. 1995 Apr;21(4):1011-7 - PubMed
  9. Aliment Pharmacol Ther. 1999 Nov;13(11):1429-36 - PubMed
  10. Baillieres Clin Gastroenterol. 1997 Jun;11(2):257-70 - PubMed
  11. J Gastroenterol Hepatol. 1998 Oct;13(10):1061-7 - PubMed
  12. Leber Magen Darm. 1996 Sep;26(5):254, 257-9 - PubMed
  13. Am J Gastroenterol. 2000 Oct;95(10):2888-93 - PubMed
  14. Am J Gastroenterol. 1998 Jan;93(1):71-4 - PubMed
  15. J Gastroenterol Hepatol. 1998 Oct;13(10):977-9 - PubMed
  16. Gut. 1992 May;33(5):715-7 - PubMed
  17. Am J Gastroenterol. 1987 Dec;82(12):1333-4 - PubMed
  18. Hepatology. 1984 May-Jun;4(3):355-8 - PubMed
  19. Eur J Gastroenterol Hepatol. 1998 Jun;10(6):509-12 - PubMed
  20. J Clin Gastroenterol. 1998 Jun;26(4):345-6 - PubMed
  21. Gastrointest Endosc. 1999 Apr;49(4 Pt 1):417-23 - PubMed
  22. Gastroenterol Clin North Am. 1993 Dec;22(4):875-89 - PubMed
  23. Hepatology. 1987 May-Jun;7(3):437-41 - PubMed
  24. Hum Pathol. 1991 Oct;22(10):1053-5 - PubMed
  25. Dig Dis. 1999;17(2):123 - PubMed
  26. Gut. 1999 May;44(5):739-42 - PubMed
  27. Dig Dis Sci. 1996 Dec;41(12):2440-6 - PubMed
  28. Lancet. 1991 Jun 15;337(8755):1431-4 - PubMed
  29. Hepatology. 1994 Aug;20(2):336-41 - PubMed
  30. Am J Clin Pathol. 1994 Aug;102(2):194-8 - PubMed
  31. Hepatology. 1994 Jan;19(1):55-60 - PubMed
  32. J Hepatol. 1994 Sep;21(3):461-7 - PubMed
  33. Am J Gastroenterol. 1990 Jan;85(1):34-7 - PubMed
  34. Lasers Surg Med. 1992;12(5):478-81 - PubMed
  35. J Gastroenterol Hepatol. 1996 Mar;11(3):270-4 - PubMed
  36. Am J Surg Pathol. 1987 Oct;11(10):750-7 - PubMed
  37. Gut. 1998 May;42(5):750-2 - PubMed
  38. Endosc Surg Allied Technol. 1994 Feb;2(1):42-6 - PubMed
  39. Am J Gastroenterol. 2000 Oct;95(10):2682-4 - PubMed
  40. Gastrointest Endosc. 1989 Jul-Aug;35(4):324-8 - PubMed
  41. Gut. 1994 Apr;35(4):461-3 - PubMed

Publication Types